CNBC’s Jim Cramer said Tuesday it appears that cannabis companies could be seeing some “meaningful differentiation.”
He took a look at the chart patterns of stocks in the sector as interpreted by Tim Collins, a technician and Cramer colleague at RealMoney.com.
“The charts, as interpreted by Tim Collins, suggest that GW Pharma and Village Farms are buys here, ” the “Mad Money” host said. “Cronos [Group] could work its way higher, although that one’s more risky. “
Cramer pointed out an ascending triangle pattern in GW Pharma’s weekly chart, which measures the stock’s price movement over a week-long period. That particular pattern, which is made up of a series of higher lows and relatively similar highs, typically tells a bullish tale.
He noted that GW Pharma does not see itself as a cannabis play, but investors see it as such because its products are inspired by the plant.
“I have been a fan of GW Pharma for a long time. A lot of that is because you can dose it. You can’t dose regular pot.” Cramer said. “The stock has had a monster run.” Cramer said. The stock has climbed nearly 90% so far this year.
Collins, Cramer said, is arguing that the stock could be able to surge to $200 if the share price ends the week above $180. It closed Tuesday at $184. If the stock instead falls under $160, then forget about it.
“I think you should stick with Canopy Growth, and Collins believes that GW Pharma is the best bet out there,” the host said.
Cramer also reviewed the chart action in Village Farms, Cronos Group, and Canopy.
Get his full insight here
Good news rally
Chinese Vice Premier Liu He (R), US Treasury Secretary Steven Mnuchin (C) and Trade Representative Robert Lighthizer pose before they proceed to their meeting at the Diaoyutai State Guesthouse in Beijing on May 1, 2019.
ANDY WONG | AFP | Getty Images
Tuesday’s stock market action is an indicator of what could come if the United States and China strike a trade deal — even if it’s a bad one, Cramer said.
The Dow Jones Industrial Average advanced nearly 200 points, the S&P 500 gained 0.85% and the tech-heavy Nasdaq Composite improved 1.08%.
“Today’s rally was a reminder that if we do get any breakthrough in the trade talks whatsoever, you’re going to get an epic rebound” thehost said. “Today may smack more of fantasy than of fact, but now you know what the market would feel like if President [Donald] Trump and the Chinese Communist Party can find a way to bury the hatchet. “
Read more here
Exciting growth phase
Dr. Vasant Narasimhan, CEO of Novartis, speaking at the Healthy Returns conference in New York City on May 21, 2019.
Astrid Stawiarz | CNBC
Novartis is entering “an exciting growth phase” as the pharmaceutical company prepares for a series of blockbuster launches this year, CEO Vasant Narasimhan told CNBC Tuesday.
“It’s a pretty exciting moment because I can’t remember a time at Novartis where year after year after year we have these significant medicines getting launched,” Narasimhan said in a sit-down interview Cramer.
Novartis has a number of drugs in the pipeline. The Swiss-based manufacturer in recent months received federal approval for Mayzent to treat multiple sclerosis and RTH258 to treat eye disease. The company is also gearing up to roll out Zolgensma for gene therapy this year, Narasimhan said.
Read more about the interview here
A Q1 blip
James Cline, CEO, Trex
Scott Mlyn | CNBC
Shares of Trex, the wood-alternative manufacturer of outdoor decking, took a “sizeable hit” after shareholders learned that a new product the company introduced had a “tough start” in the first quarter, CEO Jame Cline told Cramer.
That cost the company $10 million in pre-tax dollars, he said.
“We told [investors] that it was gonna take another quarter to work our way through that,” Cline said. “In the second half, we predicted that we’d make that up and end up with incremental margins by the full-year end.”
While there was an issue with the product roll out, Cline confirmed that overall demand was not an hindrance to the company.
“One of the challenges is there was more demand than what we had anticipated,” he said.
Catch the full interview here
Forbidden city of stocks
Cramer said that there is a shortage of buyable stocks on the market.
“When I say buyable, I mean stocks that’ll let you, kind of, sleep comfortably at night, or at least take a light nap,” th host said.
Cramer reviewed which segments of the market money managers fear right now — the sectors he has framed, at least temporarily, as the “forbidden city of stocks.”
Get the full list here
Cramer’s lightning round: McDonald’s is ‘one of the greatest stocks of our time’
In Cramer’s lightning round, the “Mad Money” host zipped through his thoughts about caller stock picks.
Nektar Therapeutics: “Nektar’s pretty good. The problem is that group is so bad, it is a total spec on oncology and pain. Why not own Novartis. That’s not a spec. You’ve got growth and you’ve got yield. How can you beat that? “
McDonald’s Corp.: “Intel, not so great. I don’t feel it there. Exxon, I don’t like the fossil. McDonald’s is one of the greatest stocks of our time, and I pounded that thing every time it is down. And do you think that Mr. [CEO Steve] Easterbrook has come on this show? I have had McMuffins, I’ve had Big Macs and fries. It has meant nothing, nothing to Mr. Easterbrook. Until he comes here, I’m just gonna keep recommending his stock. “
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
– Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? email@example.com